CD274 and neoplasm: Currently, an Adnectin (ADX_5322_A02)-based anti-human PD-L1 (hPD-L1) probe, 18F-labeled BMS-986192 has produced a high-contrast imaging of PD-L1 positive lesions, and confirmed the correlation between the tumor uptake of the probe with the PD-L1 expression in patients with advanced non-small cell lung carcinoma (NSCLC) [18–20].